Euroapi Company Header Euroapi Company Header

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu
    [{"orgOrder":0,"company":"Cilcare","sponsor":"Shionogi","pharmaFlowCategory":"D","amount":"$16.0 million","upfrontCash":"$16.0 million","newsHeadline":"Japan's Shionogi Inks \u20ac400 M Deal with French Firm Cilcare","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","highestDevelopmentStatus":"Phase I","country":"FRANCE","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2024","url1":"","url2":"","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase I"}]

    Find Clinical Drug Pipeline Developments & Deals by Cilcare

    Menu

    Cilcare

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    VIDEO(s)

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Loading...

    All Data

    Previous
    Next
    Filters Filter
    ×
    FILTER:
    filter Company
      filter Sponsor
        filter Country
          filter Therapeutic Area
            filter Study Phase

              Active Filter(s):

              refreshFilters
              refreshReset Filter
              refresh Reset Filter
              price-trend All Developments

              Companies By Therapeutic Area

              Development Status

              Cilcare

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag France
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Japan's Shionogi Inks €400 M Deal with French Firm Cilcare

              Details:

              Through the agreement with Cilcare to acquire the exclusive license to develop, manufacture, and commercialize CIL001 for the treatment of patients with hearing loss.

              Lead Product(s): CIL001

              Therapeutic Area: Otolaryngology (Ear, Nose, Throat) Product Name: CIL001

              Highest Development Status: Phase I Product Type: Small molecule

              Partner/Sponsor/Collaborator: Shionogi

              Deal Size: $16.0 million Upfront Cash: $16.0 million

              Deal Type: Agreement June 10, 2024

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity
              Farmhispania Group, a leading European CDMO in HPAPI Technologies & High Potency Fermentation.
              One Pharma aims to be one of the leading generic companies in Europe.
              Post Enquiry
              POST ENQUIRY